logo-loader
HealthPharma & Biotech
AstraZeneca

AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism

diabetes on a dial
Type-1 diabetes is a chronic disease where the pancreas produces little or no insulin

AstraZeneca PLC (LON:AZN) has won regulatory approval for a breakthrough diabetes drug with its new product Forxiga becoming the first oral treatment for the type-1 form of the disease in Europe.

It will be used as an “adjunct” to insulin for people whose glucose levels are not adequately controlled with the hormone alone.

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism.

It is estimated that there are just over 300,000 UK sufferers of type-1 diabetes, a chronic disease that means pancreas produces little or no insulin.

The condition is caused by an autoimmune reaction that destroys the beta cells in the pancreas, which make insulin.

Quick facts: AstraZeneca

Price: £74.12

Market: LSE
Market Cap: £97.24 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Brickability Group PLC looks to raise £57mln as it lists in London

Brickability Group PLC's chairman John Richards chats to Proactive's Andrew Scott ahead of the firm's listing next week in London. It plans to raise £57mln as part of the initial public offering, valuing it at around £150mln. The Bridgend-based company, which counts Redrow plc (LON:RRW)...

7 hours, 51 minutes ago

2 min read